

Special Issue

RKIP: A Pivotal Gene Product in the Pathogenesis of Cancer

Message from the Guest Editor

The scope of this Special Issue is to present up-to-date reviews and original research articles on the fast-moving field regarding the pivotal role of Raf kinase inhibitor protein (RKIP) in many vital cellular processes and disease manifestations. RKIP has been reported as a tumor suppressor, an immune enhancer, a prognostic/diagnostic biomarker, and a therapeutic target. The Special Issue will include different themes on RKIP, such as the general properties of RKIP in human malignancies, its regulation by phosphorylation and micro-RNAs, signaling cross-talks, gene products regulated by RKIP or gene products that regulate RKIP expression in various cancers, the pleiotropic activities of RKIP in cancer, response to photo-oxidative damage, the role in hypoxia and cellular stress, cellular plasticity of RKIP, the role in inflammation, the role of RKIP as a prognostic/diagnostic marker, new agents as therapeutic targets directed against RKIP, used alone or in combination, in the treatment of resistant cancers to conventional therapies, etc. Manuscripts that discuss future directions and future perspectives are also welcome.

Guest Editor

Prof. Dr. Benjamin Bonavida

Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA 90095, USA

Deadline for manuscript submissions

closed (30 October 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/71001

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)